Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZIKV-IG in Healthy Volunteers
NCT03624946Phase 1Completed
- Sponsor
- Emergent BioSolutions
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Zika virus infection comparing ZIKV-IG with Placebo (2 arms). Primary endpoint: Number of Subjects With Adverse Events. Started Jun 2018; status: completed.
02
Drugs
Zika virus immune globulin
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03624946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624946.